OR WAIT null SECS
Successor to current CEO Olivier Brandicourt is announced.
Sanofi's Board of Directors have appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt, who is retiring. Hudson, 51, most recently Chief Executive Officer of Novartis, will take over on September 1.
Hudson, who will move to Paris for the role, has spent his 28-year career with major pharma companies. Serge Weinberg, Chairman of the Board of Directors of Sanofi, commented: "[Hudson's] skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."